Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
    • Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
      • 1-Minute Consult
      • Commentary
      • Current Drug Therapy
      • Editorial
      • Guidelines to Practice
      • Interpreting Key Trials
      • Letter to the Editor
      • Review
      • Smart Testing
      • Symptoms to Diagnosis
      • The Clinical Picture
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
  • COVID-19
    • Curbside Consults Overview
    • Pulmonary/ICU
    • Patient Subsets & Specific Organ Involvement
    • Therapies
    • Imaging & Procedures
    • Patients with Underlying Disease
    • Virus Background & Testing
    • Healthcare System Practice
  • Conference Coverage
    • ASH Annual Meeting
    • AHA Sessions 2020
    • IDWeek 2020
    • CHEST 2020
    • ADA 2020
    • ACC 2020
  • Advertise
    • Media Kit
    • Contact
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
    • Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
  • COVID-19
    • Curbside Consults Overview
    • Pulmonary/ICU
    • Patient Subsets & Specific Organ Involvement
    • Therapies
    • Imaging & Procedures
    • Patients with Underlying Disease
    • Virus Background & Testing
    • Healthcare System Practice
  • Conference Coverage
    • ASH Annual Meeting
    • AHA Sessions 2020
    • IDWeek 2020
    • CHEST 2020
    • ADA 2020
    • ACC 2020
  • Advertise
    • Media Kit
    • Contact
Commentary

Emerging blood-based biomarkers for Alzheimer disease

Lynn M. Bekris, PhD and James B. Leverenz, MD
Cleveland Clinic Journal of Medicine September 2020, 87 (9) 537-539; DOI: https://doi.org/10.3949/ccjm.87a.20133
Lynn M. Bekris
Associate Staff, Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic; Assistant Professor of Molecular Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: bekrisl@ccf.org
James B. Leverenz
Director, Cleveland Lou Ruvo Center for Brain Health, Neurological Institute, and Joseph Hahn, MD, Endowed Chair of the Cleveland Clinic Neurological Institute, Cleveland Clinic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading
PDF extract preview

You do not have access to the full text of this article, the first page of the PDF of this article appears above.

REFERENCES

  1. ↵
    1. Alzheimer’s Association
    . 2020 Alzheimer’s disease facts and figures. Alzheimers Dement 2020 Mar 10. doi:10.1002/alz.12068
    OpenUrlCrossRef
  2. ↵
    1. Gallardo G,
    2. Holtzman DM
    . Amyloid-ß and tau at the crossroads of Alzheimer’s disease. Adv Exp Med Biol 2019; 1184:187203. doi:10.1007/978-981-32-9358-8_16
    OpenUrlCrossRef
  3. ↵
    1. Cohen AD,
    2. Landau SM,
    3. Snitz BE,
    4. Klunk WE,
    5. Blennow K,
    6. Zetterberg H
    . Fluid and PET biomarkers for amyloid pathology in Alzheimer’s disease. Mol Cell Neurosci 2019; 97:3–17. doi:10.1016/j.mcn.2018.12.004
    OpenUrlCrossRef
  4. ↵
    1. Schöll M,
    2. Maass A,
    3. Mattsson N, et al
    . Biomarkers for tau pathology. Mol Cell Neurosci 2019; 97:18–33. doi:10.1016/j.mcn.2018.12.001
    OpenUrlCrossRef
  5. ↵
    1. Boyle PA,
    2. Yu L,
    3. Leurgans SE, et al
    . Attributable risk of Alzheimer’s dementia attributed to age-related neuropathologies. Ann Neurol 2019;85(1):114–124. doi:10.1002/ana.25380
    OpenUrlCrossRef
  6. ↵
    1. Olsson B,
    2. Lautner R,
    3. Andreasson U, et al
    . CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis. Lancet Neurol 2016;15(7):673–684. doi:10.1016/S1474-4422(16)00070-3
    OpenUrlCrossRefPubMed
  7. ↵
    1. Zetterberg H,
    2. Mörtberg E,
    3. Song L, et al
    . Hypoxia due to cardiac arrest induces a time-dependent increase in serum amyloid ß levels in humans. PloS One 2011; 6(12):e28263. doi:10.1371/journal.pone.0028263
    OpenUrlCrossRefPubMed
    1. Janelidze S,
    2. Stomrud E,
    3. Palmqvist S, et al
    . Plasma ß-amyloid in Alzheimer’s disease and vascular disease. Sci Rep 2016; 6:26801. doi:10.1038/srep26801
    OpenUrlCrossRefPubMed
    1. Verberk IMW,
    2. Slot RE,
    3. Verfaillie SCJ, et al
    . Plasma amyloid as prescreener for the earliest Alzheimer pathological changes. Ann Neurol 2018;84(5):648–658. doi:10.1002/ana.25334
    OpenUrlCrossRef
    1. Nakamura A,
    2. Kaneko N,
    3. Villemagne VL, et al
    . High performance plasma amyloid-ß biomarkers for Alzheimer’s disease. Nature 2018;554(7691):249–254. doi:10.1038/nature25456
    OpenUrlCrossRef
  8. ↵
    1. Ovod V,
    2. Ramsey KN,
    3. Mawuenyega KG, et al
    . Amyloid ß concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement 2017;13(8):841–849. doi:10.1016/j.jalz.2017.06.2266
    OpenUrlCrossRef
  9. ↵
    1. Mielke MM,
    2. Hagen CE,
    3. Wennberg AMV, et al
    . Association of plasma total tau level with cognitive decline and risk of mild cognitive impairment or dementia in the Mayo Clinic Study on Aging. JAMA Neurol 2017;74(9):1073–1080. doi:10.1001/jamaneurol.2017.1359
    OpenUrlCrossRef
  10. ↵
    1. Pase MP,
    2. Beiser AS,
    3. Himali JJ, et al
    . Assessment of plasma total tau level as a predictive biomarker for dementia and related endophenotypes. JAMA Neurol 2019;76(5):598–606. doi:10.1001/jamaneurol.2018.4666
    OpenUrlCrossRef
  11. ↵
    1. Mielke MM,
    2. Hagen CE,
    3. Xu J, et al
    . Plasma phospho-tau181 increases with Alzheimer’s disease clinical severity and is associated with tau-and amyloid-positron emission tomography. Alzheimers Dement 2018;14(8):989–997. doi:10.1016/j.jalz.2018.02.013
    OpenUrlCrossRefPubMed
    1. Yang C-C,
    2. Chiu M-J,
    3. Chen T-F, et al
    . Assay of plasma phosphorylated tau protein (threonine 181) and total tau protein in early-stage Alzheimer’s disease. J Alzheimers Dis 2018;61(4):1323–1332. doi:10.3233/JAD-170810
    OpenUrlCrossRef
  12. ↵
    1. Tatebe H,
    2. Kasai T,
    3. Ohmichi T, et al
    . Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer’s disease and Down syndrome. Mol Neurodegener 2017; 12(1):63. doi:10.1186/s13024-017-0206-8
    OpenUrlCrossRef
  13. ↵
    1. Palmqvist S,
    2. Janelidze S,
    3. Quiroz YT, et al
    . Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA 2020 Jul 28. doi:10.1001/jama.2020.12134
    OpenUrlCrossRef
  14. ↵
    1. Barthélemy NR,
    2. Horie K,
    3. Sato C,
    4. Bateman RJ
    . Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer’s disease. J Exp Med 2020; 217(11):e20200861. doi:10.1084/jem.20200861
    OpenUrlCrossRef
  15. ↵
    1. Carrillo MC,
    2. Blennow K,
    3. Soares H, et al
    . Global standardization measurement of cerebral spinal fluid for Alzheimer’s disease: an update from the Alzheimer’s Association Global Biomarkers Consortium. Alzheimers Dement 2013;9(2):137–140. doi:10.1016/j.jalz.2012.11.003
    OpenUrlCrossRefPubMed

This article requires you to have a ccjm.org account to view the full text. If you already have an account, you may log in below to view this article along with all other CCJM content. If you do not have an account, register here. It’s free!

Log in using your username and password

Forgot your user name or password?
PreviousNext
Back to top

Registration is Now Required for Free Access to CCJM Content

Register once and log in for full access to articles and content. Click “Register” in the upper right corner and follow the simple instructions to create a new account.

If you are using a mobile device, click on the settings icon to access the Register link.

In this issue

Cleveland Clinic Journal of Medicine: 87 (9)
Cleveland Clinic Journal of Medicine
Vol. 87, Issue 9
1 Sep 2020
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Emerging blood-based biomarkers for Alzheimer disease
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
2 + 2 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Emerging blood-based biomarkers for Alzheimer disease
Lynn M. Bekris, James B. Leverenz
Cleveland Clinic Journal of Medicine Sep 2020, 87 (9) 537-539; DOI: 10.3949/ccjm.87a.20133

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Emerging blood-based biomarkers for Alzheimer disease
Lynn M. Bekris, James B. Leverenz
Cleveland Clinic Journal of Medicine Sep 2020, 87 (9) 537-539; DOI: 10.3949/ccjm.87a.20133
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Linkedin Share Button

Jump to section

  • Article
    • DEMENTIA’S TOLL
    • EARLY CHANGES IN THE BRAIN ARE HARD TO DETECT
    • SEARCHING FOR A BLOOD-BASED BIOMARKER
    • STUDIES UNDER WAY
    • REFERENCES
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Cleveland Clinic—A century of progress
  • Cleveland Clinic Journal of Medicine: Evolution and a look ahead
  • COVID-19 diagnostic testing and the psychology of precautions fatigue
Show more Commentary

Similar Articles

Subjects

  • Women's Health
  • Neurology
  • Geriatrics

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit
  • Advertise Contact

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • Advertisers
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2021 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire